Emergent BioSolutions Awarded $30 Million Contract Modification for CYFENDUS®, a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use
On Sept. 2, 2025, Emergent BioSolutions announced it had received a $30 million contract modification from the Biomedical Advanced…